Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061022 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,200
- Enrollment target
NCT00061022: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00061022 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 3,200 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (315% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00061022, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,200 participants
- Enrollment target
Study Summary
This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.
Interventions
- DRUG NXY-059
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,200 participants |
| Start Date | 2003-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00061022 record still lists
NCT00061022 is an interventional study that assigns participants to a tested intervention. Its 3,200 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (315% higher).
The record links to 0 conditions, and to 1 intervention - of which NXY-059 is the first listed.
NCT00061022 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00061022 about?
NCT00061022 is a clinical study titled "Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke". This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.
What is the current status of trial NCT00061022?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,200 participants. The study started on 2003-05. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00061022?
The interventions under investigation include: NXY-059 (DRUG).
Who is sponsoring clinical trial NCT00061022?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00061022's enrollment target sits among peer trials
3,200 73rd of 2000 higher than 1,927 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043457 · 3,200 participants
Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
- NCT04045665 · 3,200 participants · Phase 3
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- NCT05381766 · 3,200 participants · NA
Building Access to Food Through Systems and Solidarity
- NCT06042543 · 3,200 participants · NA
Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia